AVEO Licenses Early-Stage RON-Targeted Antibodies to Centocor Ortho Biotech
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 6 (Table of Contents)
Published: 9 Jun-2011
DOI: 10.3833/pdr.v2011.i6.1481 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AVEO Pharmaceuticals has signed a global licensing deal with Johnson & Johnson’s (J&J’s) Centocor Ortho Biotech division for the development and commercialisation of its internally discovered RON (Recepteur d’Origine Nantais)-targeted antibodies, which have demonstrated strong antitumour activity in preclinical studies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS